Brief: GlobeImmune says top line results from GS-4774 phase 2 trial in virally-suppressed chronic HBV patients

GlobeImmune

27/05/2015 11:30

May 27 (Reuters) - GlobeImmune Inc  GBIM.O : 
 * Announces top line results from GS-4774 phase 2 trial in virally-suppressed 
   chronic HBV patients 
 * GS-4774 was found to be generally safe and well tolerated, with injection 
   site reactions identified as the primary adverse event 
 * Patients treated with highest dose plus ongoing oral antiviral therapy did 
   not show a reduction in Hepatitis B surface antigen at week 24 
 
 * Source text for Eikon  ID:nMKW2SH1ra  
 
 * Further company coverage  GBIM.O  
 
 ((Bengaluru Newsroom; +1 646 223 8780))